Viz.ai Introduced New Artificial Intelligence Algorithm for Hypertrophic Cardiomyopathy

Viz.ai has unveiled a groundbreaking artificial intelligence algorithm designed to revolutionise the early detection and management of hypertrophic cardiomyopathy (HCM).

This innovative AI detection algorithm has led to the establishment of a new regulatory category specifically catered to cardiovascular machine learning-based notification software.

The Viz HCM module operates autonomously, meticulously analysing routine electrocardiograms (ECGs) gathered from various healthcare facilities to pinpoint potential instances of HCM.

Once detected, the module promptly notifies relevant cardiologists and the care team through the Viz mobile application. This initiates a seamless process whereby clinicians can review the patient's ECG, effectively coordinate subsequent steps such as arranging an echocardiogram for a definitive diagnosis, and utilise the Viz Echo Viewer to assess images and access echocardiogram reports.

Hypertrophic cardiomyopathy is a devastating ailment that frequently evades detection until it reaches an advanced stage. The integration of the Viz HCM module into the Viz.ai Platform is aimed squarely at ameliorating patient outcomes by expediting the referral of these cases to specialised experts in a more timely manner.

The AI-powered Viz HCM module holds the potential to speed up the identification and treatment of patients with this common inherited heart condition.

Viz.ai has received first FDA Dae Novo approval for an AI algorithm dedicated to detecting Hypertrophic Cardiomyopathy (HCM).